• NBIP-'2118 targets a new, non-incretin mechanism for weight loss with lean mass preservation

SAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'2118 in adult participants. NBIP-'2118 is an investigational corticotropin-releasing factor type 2 receptor (CRF2) peptide agonist and a potential first-in-class therapy for obesity.